Skip to main content
. 2019 Oct 17;10:1188. doi: 10.3389/fphar.2019.01188

Figure 5.

Figure 5

Phil inhibits RANKL-stimulated JNK and ERK activations. (A) After treating BMM cells with different doses of Phil for 4 h, RANKL (100ng/ml) was added to stimulate for 15 min. Protein was then extracted for Western blot with the indicated antibodies. (B) The ratios of p-JNK/JNK and p-ERK/ERK were determined using ImageJ software. n = 3, ###P<0.001 relative to RANKL-untreated, Phil-untreated group; *P<0.05, **P<0.01 and ***P<0.001 relative to RANKL-induced, Phil-untreated group. (C) BMM cells were treated with Phil (10µM) for 0, 1, 3, or 5 days. Western blot was used to examine the protein levels of c-Fos, NFATc1, and GAPDH. (D) The ratios of c-Fos/GAPDH and NFATc1/GAPDH were analyzed using ImageJ software. n = 3, **P<0.01 and ***P<0.001 relative to RANKL-induced, Phil -untreated group.